Great expectations of Danish cancer drug candidates  

2008.01.07
Three Danish biotech companies are each developing a cancer drug which could ensure Denmark a leading position in the battle against cancer
Three Danish biotech companies are each developing a promising cancer drug which could ensure Denmark a leading position in the battle against cancer, reports national daily newspaper Berlingske Tidende. Genmab, TopoTarget and Santaris Pharma are developing a new class of drugs which reportedly have significantly fewer side effects than medicines currently used for the treatment of cancer.
 
"We have great expectations of the new class of drugs that the three companies are developing," said Partner in BankInvest Thomas Tscherning. "One of the big problems today is that cancer drugs have some serious side effects that often affect patients just as severely as the disease itself."
 
Tscherning points out however that there are still a number of things that can go wrong during the final drug development stages. Drugs in phase II typically have a 40% chance of making it to market, while in phase III the chance improves to 70-80%.
 
Director of TopoTarget Peter Buhl Jensen commented to Berlingske that is quite unique for a small country like Denmark to have so many groundbreaking products on the way. "It is many years of good and effective cancer research in this country, from which we now have started to see the results in form of a number of promising products."
 
Link > Genmab  
Link > TopoTarget  
Link > Santaris Pharma  

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×